CAR T-cell Therapy Market, By Product Type (Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, and Yescarta), By Target Antigen, By Indication, By End user, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4504
|
Published Date
November 2025
|
Pages
365
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
CAR T-cell Therapy Market size was valued at US$ 5,678 Million in 2024, expanding at a CAGR of 38.5% from 2025 to 2032.
CAR T-cell therapy involves engineered immune cell treatments that modify a patient’s T cells to specifically target and destroy cancer cells. Initially approved for certain hematologic malignancies, such as relapsed or refractory blood cancers, CAR T-cell therapy is now being actively investigated for solid tumors as well. The market is experiencing rapid growth driven by robust clinical outcomes, an expanding research pipeline, increasing regulatory approvals, and growing investments from biopharmaceutical companies and specialty cell therapy manufacturers. However, the sector faces challenges, including complex manufacturing processes, the requirement for specialized treatment centers, and high therapy costs. Despite these hurdles, advances in manufacturing scale-up, strategic partnerships, and next-generation CAR designs are supporting broader commercialization and market expansion. In China, government-backed investment in cell and gene therapies surged in 2023, reaching approximately US$2.5billion, with over 1,100 active CART trials underway.
CAR T-cell Therapy Market- Market Dynamics
Enhanced Clinical Efficacy and Sustained Remissions
CAR T-cell therapy has demonstrated significant clinical efficacy and durable remissions in patients with relapsed or refractory hematologic malignancies. Evidence from clinical trials and real-world applications indicates that the therapy can achieve long-term responses even in cases where conventional treatments have failed. These positive outcomes are driving broader adoption by healthcare providers, encouraging payers to support coverage despite high costs, and attracting substantial investment from pharmaceutical companies and cell therapy manufacturers seeking to expand indications and scale production. Global governments are actively supporting this transformation: for example, France’s “France2030” program awarded Allogenica a €2.5million grant to scale up production of a universal CART therapy.
CAR T-cell Therapy Market- Key Insights
- According to our research analysis, the global CAR Tcell therapy market is projected to grow at a CAGR of approximately 38.5% during the forecast period from 2025 to 2032.
- By product type, Kymriah is expected to hold the largest market share in 2024.
- In terms of target antigen, CD19 emerged as the leading target in 2024.
- Based on indication, acute lymphoblastic leukemia (ALL) was the dominant segment in 2024.
- By end user, cancer treatment centers represented the largest segment in 2024.
- Regionally, North America led the market in revenue generation in 2024.
CAR T-cell Therapy Market- Segmentation Analysis:
The Global CAR T-cell Therapy Market is segmented on the basis of Product Type, Target Antigen, Indication, End user, and Region.
The CART cell therapy market is broadly segmented by product type into seven categories—Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and Others. Among these, established therapies like Kymriah and Yescarta continue to dominate the market. Their leadership stems from deeper clinical experience, broader regulatory approvals, and mature commercial infrastructures. In fact, according to Grand View Research, the Yescarta segment alone held about 50percent of the global CART market in 2024, underscoring the entrenched position of these early leaders.
When we look at the market by target antigen, it again divides into seven groups: CD19, BCMA, CD22, GD2, HER2, GPC3, and Others (such asEGFRvIII, CD7, CD123, mesothelin). Here, CD19-targeted CART therapies remain the most dominant, largely due to the long-running success of early products like Kymriah and Yescarta. Marketforecasting research suggests that CD19-directed therapies may continue to make up over 65percent of the overall antigentarget market through the middle of the next decade. Meanwhile, BCMA, which is primarily expressed in multiple myeloma, is emerging as the fastest-growing target. This is driven by the strong clinical responses of BCMA CARs like Carvykti and Abecma, and the rapid pipeline expansion around this antigen.
In terms of disease indication, the market is generally classified into four areas: Acute Lymphoblastic Leukemia (ALL), Lymphoma, Multiple Myeloma, and Mantle Cell Lymphoma. Today, multiple myeloma represents the most significant near-term growth opportunity, fueled by the commercial traction of BCMA-targeted CAR Ts. However, hematologic malignancies (ALL, various lymphomas, and myeloma) continue to be the mainstay of current CART usage, because most approved products and physician experience are already concentrated in these areas. Long term, solid tumors may offer the largest market potential, but translation into broad commercialization is slower due to biological and translational challenges. Researchanalysis firms expect the multiple myeloma segment to grow rapidly, reflecting increasing clinical adoption.
Finally, by end user, the market is split between hospitals and specialized cancer treatment centers. Hospitals dominate today, accounting for a large majority of CART delivery. For example, one marketreport shows hospitals contributed about 55percent of global CART revenues in 2024, thanks to their advanced infrastructure, in-house labs, and capacity to manage the complex stages of CART treatment—including apheresis, cell manufacturing, reinfusion, and sideeffect management. These centers remain the backbone of CART adoption given their multidisciplinary teams and capacity to handle inpatient monitoring for toxicities such as cytokine release syndrome.
CAR T-cell Therapy Market- Competitive Landscape:
The competitive landscape of the CAR Tcell therapy market is dominated by a combination of large biotech and pharmaceutical companies with approved CAR T products, alongside numerous smaller innovators and academic spinouts developing next-generation and allogeneic therapies. Competition primarily focuses on clinical performance, safety (minimizing cytokine release syndrome and neurotoxicity), manufacturing scale and cost, and commercial partnerships for production and distribution. Strategic activities such as mergers and acquisitions, licensing agreements, and alliances are common as companies aim to secure pipelines and expand manufacturing capacity.
Recent Developments:
- On November 5, 2025, Indian Prime Minister Narendra Modi unveiled three national innovations at ESTIC2025, including QSIP, a 25qubit quantum processing unit, and NexCAR19, India’s first indigenous CART therapy developed by ImmunoACT. The development was supported by DBT and BIRAC, which also funded a 200L GMP lentiviral production platform expected to serve approximately 1,000 patients annually. Ongoing DBT and BIRAC funding continues to support CART research targeting both hematologic malignancies and solid tumors.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- ALLOGENE THERAPEUTICS
- Aurora Biopharma
- Bristol-Myers Squibb company
- Cartesian Therapeutics, Inc.
- Curocell Inc
- Gilead Sciences
- Johnson & Johnson Services, Inc.
- JW Therapeutics
- Lonza
- Novartis
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Tecartus
- Yescarta
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY TARGET ANTIGEN- MARKET ANALYSIS, 2019 - 2032
- CD19
- BCMA (B-cell Maturation Antigen)
- CD22
- GD2
- HER2
- GPC3
- Others (e.g., EGFRvIII, CD7, CD123, mesothelin)
GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Acute lymphoblastic leukemia
- Lymphoma
- Multiple Myeloma
- Mantle Cell Lymphoma
GLOBAL CAR T-CELL THERAPY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Cancer Treatment Centers
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. CAR T-cell Therapy Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. CAR T-cell Therapy Market Snippet by Product Type
2.1.2. CAR T-cell Therapy Market Snippet by Target Antigen
2.1.3. CAR T-cell Therapy Market Snippet by Indication
2.1.4. CAR T-cell Therapy Market Snippet by End user
2.1.5. CAR T-cell Therapy Market Snippet by Country
2.1.6. CAR T-cell Therapy Market Snippet by Region
2.2. Competitive Insights
3. CAR T-cell Therapy Key Market Trends
3.1. CAR T-cell Therapy Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. CAR T-cell Therapy Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. CAR T-cell Therapy Market Opportunities
3.4. CAR T-cell Therapy Market Future Trends
4. CAR T-cell Therapy Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. CAR T-cell Therapy Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. CAR T-cell Therapy Market Landscape
6.1. CAR T-cell Therapy Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. CAR T-cell Therapy Market – By Product Type
7.1. Overview
7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
7.1.2. Abecma
7.1.3. Breyanzi
7.1.4. Carvykti
7.1.5. Kymriah
7.1.6. Tecartus
7.1.7. Yescarta
7.1.8. Others
8. CAR T-cell Therapy Market – By Target Antigen
8.1. Overview
8.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
8.1.2. CD19
8.1.3. BCMA (B-cell Maturation Antigen)
8.1.4. CD22
8.1.5. GD2
8.1.6. HER2
8.1.7. GPC3
8.1.8. Others (e.g., EGFRvIII, CD7, CD123, mesothelin)
9. CAR T-cell Therapy Market – By Indication
9.1. Overview
9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
9.1.2. Acute lymphoblastic leukemia
9.1.3. Lymphoma
9.1.4. Multiple Myeloma
9.1.5. Mantle Cell Lymphoma
10. CAR T-cell Therapy Market – By End user
10.1. Overview
10.1.1. Segment Share Analysis, By Target Antigen, 2024 & 2032 (%)
10.1.2. Hospitals
10.1.3. Cancer Treatment Centers
10.1.4. Others
11. CAR T-cell Therapy Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. CAR T-cell Therapy Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. CAR T-cell Therapy Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. CAR T-cell Therapy Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. CAR T-cell Therapy Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. CAR T-cell Therapy Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Target Antigen, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End user, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- CAR T-cell Therapy Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. XX
12.2.2. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- ALLOGENE THERAPEUTICS
- Aurora Biopharma
- Bristol-Myers Squibb company
- Cartesian Therapeutics, Inc.
- Curocell Inc
- Gilead Sciences
- Johnson & Johnson Services, Inc.
- JW Therapeutics
- Lonza
- Novartis
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Tecartus
- Yescarta
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY TARGET ANTIGEN- MARKET ANALYSIS, 2019 - 2032
- CD19
- BCMA (B-cell Maturation Antigen)
- CD22
- GD2
- HER2
- GPC3
- Others (e.g., EGFRvIII, CD7, CD123, mesothelin)
GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Acute lymphoblastic leukemia
- Lymphoma
- Multiple Myeloma
- Mantle Cell Lymphoma
GLOBAL CAR T-CELL THERAPY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Cancer Treatment Centers
- Others
GLOBAL CAR T-CELL THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
